Why Insmed (INSM) Stock Is Up Today

Insmed Incorporated (INSM) is up 3.1% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is a mix of upbeat messaging at today’s investor conference and continued enthusiasm around Insmed’s respiratory franchise. Management highlighted stronger long-term commercial expectations, ongoing launch momentum for BRINSUPRI, and additional pipeline progress, which likely reinforced bullish sentiment.

Details:

At a healthcare conference on September 9, management discussed a higher peak sales outlook, with total peak revenue expectations for its three lead programs now above $14 billion.

The company’s latest quarterly update raised 2026 BRINSUPRI revenue guidance to $1.25 billion to $1.40 billion, while keeping ARIKAYCE guidance at $450 million to $470 million.

Insmed also said it had about $1.2 billion in cash, cash equivalents, and marketable securities as of June 30, 2026, supporting commercialization and late-stage development plans.

Recent scientific visibility may also be helping sentiment after the company highlighted new respiratory data presentations at the European Respiratory Society Congress, including ARIKAYCE and BRINSUPRI analyses and TPIP-related research.

Sources:

Insmed Investor Relations, SEC, StockAnalysis

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$INSM Insider Trading Activity

$INSM insiders have traded $INSM stock on the open market 52 times in the past 6 months. Of those trades, 0 have been purchases and 52 have been sales.

Here’s a breakdown of recent trading of $INSM stock by insiders over the last 6 months:

ROGER ADSETT (Chief Operating Officer) has made 0 purchases and 6 sales selling 336,117 shares for an estimated $47,382,982.
WILLIAM LEWIS (Chair and CEO) has made 0 purchases and 27 sales selling 117,162 shares for an estimated $14,334,437.
MARTINA M.D. FLAMMER (Chief Medical Officer) has made 0 purchases and 11 sales selling 75,181 shares for an estimated $8,732,031.
MICHAEL ALEXANDER SMITH (Chief Legal Officer) has made 0 purchases and 5 sales selling 33,861 shares for an estimated $4,503,162.
SARA BONSTEIN (Chief Financial Officer) has made 0 purchases and 2 sales selling 10,676 shares for an estimated $1,206,898.
MELVIN MD SHAROKY sold 5,000 shares for an estimated $637,650

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive INSM Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$INSM Hedge Fund Activity

We have seen 358 institutional investors add shares of $INSM stock to their portfolio, and 419 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 10,428,170 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,111,851,485
DARWIN GLOBAL MANAGEMENT, LTD. removed 10,374,021 shares (-61.7%) from their portfolio in Q2 2026, for an estimated $1,106,078,119
ORBIS ALLAN GRAY LTD added 4,203,663 shares (+224.5%) to their portfolio in Q2 2026, for an estimated $448,194,549
AMERIPRISE FINANCIAL INC added 3,121,853 shares (+102.1%) to their portfolio in Q2 2026, for an estimated $332,851,966
FMR LLC added 2,983,416 shares (+22.7%) to their portfolio in Q2 2026, for an estimated $318,091,813
CAPITAL INTERNATIONAL INVESTORS added 2,642,930 shares (+47.2%) to their portfolio in Q2 2026, for an estimated $281,789,196
MAVERICK CAPITAL LTD added 2,150,762 shares (+inf%) to their portfolio in Q2 2026, for an estimated $229,314,244

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$INSM Congressional Stock Trading

Members of Congress have traded $INSM stock 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $INSM stock by members of Congress over the last 6 months:

REPRESENTATIVE JOSH GOTTHEIMER sold up to $15,000 on 06/10.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$INSM Price Targets

Multiple analysts have issued price targets for $INSM recently. We have seen 15 analysts offer price targets for $INSM in the last 6 months, with a median target of $212.0.

Here are some recent targets:

Josh Schimmer from Evercore ISI Group set a target price of $160.0 on 06/22/2026
Jessica Fye from JP Morgan set a target price of $179.0 on 06/08/2026
Leonid Timashev from RBC Capital set a target price of $195.0 on 06/05/2026
Danielle Brill from Truist Securities set a target price of $185.0 on 05/14/2026
Benjamin Burnett from Wells Fargo set a target price of $160.0 on 05/08/2026
Vamil Divan from Guggenheim set a target price of $226.0 on 05/08/2026
Adam Walsh from Roth Capital set a target price of $212.0 on 04/17/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.